High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
The right dose of daunorubicin (DNR) for the treatment of newly diagnosed acute myeloid leukemia (AML) is uncertain. Previous trials have shown conflicting results concerning the efficacy of high or low doses of daunorubicin to induction chemotherapy for newly diagnosed AML. A systematic review and...
Saved in:
| Main Authors: | Qiang Gong, Lixin Zhou, Shuangnian Xu, Xi Li, Yunding Zou, Jieping Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0125612 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High-dose versus Standard-dose Daunorubicin in Induction Chemotherapy for Acute Myeloid Leukemia: A Meta-Analysis
by: Bibi Kulsoom, et al.
Published: (2025-06-01) -
Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment
by: Oudai Alkabbani, et al.
Published: (2025-07-01) -
The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX‐351) in Acute Myeloid Leukemia Patients: A Systematic Review
by: Abdulwahab M. Alzahrani, et al.
Published: (2025-05-01) -
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms
by: Naseema Gangat, et al.
Published: (2025-08-01) -
Characterization of the FLT3 Mutation in Newly Diagnosed Patients with Acute Myeloid Leukemia
by: Luay Fahad, et al.
Published: (2024-06-01)